KORU Medical Systems (NASDAQ:KRMD) Posts Earnings Results, Beats Expectations By $0.03 EPS

KORU Medical Systems (NASDAQ:KRMD) announced its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03, Zacks reports. KORU Medical Systems had a negative return on equity of 10.83% and a negative net margin of 4.03%.The business had revenue of $12.05 million for the quarter, compared to the consensus estimate of $11.62 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q2 revenue reached a record $12 million, up 18% year over year, driven by 12% growth in domestic core revenue and 59% international growth. Management said domestic demand, patient retention, new starts, and market-share gains remain strong.
• Gross margin improved to 65.1% from 63.5% a year ago, supported by manufacturing efficiencies, pricing, mix, and improved supplier terms. KORU also reported positive net income for the first time since 2019, positive operating cash flow in the quarter, and reiterated expectations for positive adjusted EBITDA for the full year.
• The company narrowed 2026 revenue guidance to $47.5 million-$48.5 million from its prior outlook, citing slower-than-expected launches in certain international, non-tender markets. Management now expects some of that prefilled-syringe opportunity to contribute more meaningfully in 2027.
• KORU withdrew its U.S. PHESGO 510(k) application after discussions with the FDA and will pursue other oncology biologics instead, delaying its planned U.S. oncology entry. PHESGO remains part of the international strategy, but additional real-world evidence and regulatory work are required.
• The company acquired connected-monitoring technology intended to add adherence tracking, real-world evidence, and patient support to its infusion platform, though management characterized it as a multi-year development effort. KORU also said Freedom 360 development has cleared its highest-risk stages and remains on track for a U.S. 510(k) submission by the end of 2027.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD traded down $0.01 during midday trading on Friday, hitting $3.55. 395,612 shares of the company’s stock were exchanged, compared to its average volume of 168,077. KORU Medical Systems has a twelve month low of $3.21 and a twelve month high of $6.61. The firm has a market cap of $163.05 million, a P/E ratio of -88.75 and a beta of 0.45. The stock’s 50 day moving average price is $4.12 and its 200-day moving average price is $4.37.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Weiss Ratings raised KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. Craig Hallum reissued a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a report on Thursday. Finally, Wall Street Zen upgraded shares of KORU Medical Systems from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Insider Buying and Selling

In other KORU Medical Systems news, insider Adam R. Kalbermatten bought 12,500 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $3.94 per share, with a total value of $49,250.00. Following the purchase, the insider directly owned 312,500 shares of the company’s stock, valued at approximately $1,231,250. The trade was a 4.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders purchased 28,000 shares of company stock valued at $109,430. 18.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KRMD. Geode Capital Management LLC grew its position in KORU Medical Systems by 101.3% in the 2nd quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after buying an additional 501,875 shares in the last quarter. First Light Asset Management LLC raised its position in shares of KORU Medical Systems by 5.1% during the 2nd quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock worth $16,760,000 after buying an additional 226,700 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after buying an additional 158,914 shares in the last quarter. State Street Corp lifted its stake in shares of KORU Medical Systems by 32.6% in the 4th quarter. State Street Corp now owns 602,645 shares of the company’s stock worth $3,501,000 after acquiring an additional 148,166 shares during the period. Finally, Informed Momentum Co LLC acquired a new stake in shares of KORU Medical Systems in the 4th quarter worth approximately $794,000. 58.60% of the stock is owned by institutional investors and hedge funds.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.